Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05087589
Other study ID # 20210918pss
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 20, 2021
Est. completion date October 1, 2023

Study information

Verified date October 2021
Source Peking University People's Hospital
Contact Qinghong Liu
Phone +86 15774917676
Email 166618530@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to explore the clinical and immunological efficacy of tofacitinib on primary Sjögren's Syndrome


Description:

The investigators designed a single center, open-label, prospective study. Adults with active primary Sjögren's Syndrome will be enrolled, meeting the American College of Rheumatology(ACR) & European allance of associations for rheumatology(EULAR)(2016) diagnostic criteria . Tofacitinib 5 mg bd was administered for 6 months to explore its efficacy and safety. The improvement of clinical and laboratory indexes was evaluated. Changes of immune cell subsets and cytokines were monitored.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date October 1, 2023
Est. primary completion date January 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female >18 years of age at screening visits 2. Patients meet the American-European Consensus Group 2002 classification criteria 3. The patient must be informed in writing of the consent to participate in the trial and the patient is expected to be able to comply with the requirements of the study follow-up plan and other protocols. 4. Dosing of antimalarials, prednisone or equivalent, cholinergic stimulants, and topical cyclosporine required to be stable for at least 4 weeks before screening and during study; maximum doses allowed: - Hydroxychloroquinone, 400 mg/day; - Prednisone, 10 mg/day Exclusion Criteria: Any subject meeting any of the following criteria should be excluded: 1. Laboratory abnormality: - Hb=9 g/dl - Neutrophil <1.0 x 109/l - lymphocyte<0.5 x 109/l 2. Diagnosis of other autoimmune disease, or other sicca syndrome. 3. Use rituximab or other monoclonal antibodies within 6 months. 4. Received high doses of glucocorticoid (>10 mg/d) within 1 month. 5. Serious complications: including heart failure (= New York Heart Association (NYHA) class III), renal insufficiency (creatinine clearance = 30 ml/min), liver dysfunction (serum Alanine transaminase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of normal, or total bilirubin greater than Normal upper limit) 6. Known allergies, hyperreactivity or intolerance of tofacitinib or its excipients. 7. Have a serious infection needing hospitalization (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or use intravenous antibiotics to treat infection in 2 months before the enrollment. 8. Infection with HIV (HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If seropositive, it is recommended to consult a doctor who has expertise in treating HIV or hepatitis C virus infection. 9. Any known history of malignancy in the past 5 years (except for non-melanoma skin cancer, non-melanoma skin cancer or cervical tumor without recurrence within 3 months after surgical cure prior to the first study preparation). 10. Uncontrolled mental or emotional disorders, including a history of drug and alcohol abuse over the past 3 years, may hinder the successful completion of the study. 11. Pregnant, lactating women (WCBP) are reluctant to use medically approved contraceptives during treatment and 12 months after treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tofacitinib
Tofacitinib 5mg was taken orally twice a day for 6 months

Locations

Country Name City State
China Department of Rheumatology and Immunology, Peking University People's Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunological Responses Analysis interleukin 17 (IL-17)-producing helper T (Th17) cells before and during tofacitinib treatment. P values below 0.05 are considered statistically significant in this study. week 24
Secondary Improvements in EULAR SS patient-reported index (ESSPRI), other clinical and immunological parameters ESSPRI ranges from 0 to 10. The patient's acceptability/satisfaction of its current state (taking account of his symptoms: dryness, fatigue and pain) should be recorded. For addressing patient-reported outcomes, we define response as an improvement of ESSPRI at least one point or 15% . week 24
Secondary Safety and tolerability of tofacitinib as assessed by incidence of adverse events reported and observed we will report frequency of adverse events.Adverse events includes infection, tumor, abnormal neutrophil and lymphocyte count, anemia,drug-induced liver and kidney damage. up tp 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03040583 - The ASSESS National Multi-center Prospective Cohort
Completed NCT01989819 - Primary Sjögren Syndrome
Completed NCT02291029 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Phase 2
Terminated NCT02610543 - UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT04975087 - The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
Completed NCT04078386 - A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04212572 - Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
Completed NCT02149420 - PD of VAY736 in Patients With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04858464 - Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
Recruiting NCT03003572 - Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
Completed NCT00632866 - Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Phase 3
Completed NCT02334306 - A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Phase 2
Completed NCT02775916 - Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Phase 2
Completed NCT02464319 - A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Phase 2
Terminated NCT01552681 - Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome Phase 2
Completed NCT04186871 - Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Phase 2
Completed NCT00426543 - Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome Phase 2
Recruiting NCT04981145 - The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome Phase 4
Completed NCT06432101 - Acupuncture Combined With Hydroxychloroquine N/A
Completed NCT03627065 - A Study of INCB050465 in Primary Sjögren's Syndrome Phase 2